The pharmaceutical industry is buzzing with anticipation as the race to acquire French biotech firm Abivax intensifies. AstraZeneca currently holds an exclusive position to evaluate Abivax for a potential takeover, a period that concludes on March 23rd. Should the British drugmaker not finalize an offer by this deadline, the landscape of this high-stakes acquisition could dramatically shift, potentially allowing other pharmaceutical giants, including Eli Lilly, to re-enter negotiations.
Details of the Potential Acquisition Battle Emerge
As of March 12, 2026, British pharmaceutical giant AstraZeneca Plc is in an exclusive window to pursue the acquisition of French biotech firm Abivax SA. This period, which began in early February, grants AstraZeneca unique access to Abivax's proprietary data for evaluation, with a firm deadline of March 23. This strategic move follows Abivax's remarkable surge in market value, which skyrocketed approximately 1,600% in 2025 to reach around 7.7 billion euros (approximately $8.9 billion). This increase was primarily driven by overwhelmingly positive Phase 3 clinical trial results for obefazimod (ABX464), its lead drug candidate for moderately to severely active ulcerative colitis.
If AstraZeneca fails to present a formal acquisition bid by the specified deadline, the exclusivity agreement will lapse. This scenario would open the door for other interested parties, most notably Eli Lilly and Co, to engage in discussions with Abivax. Eli Lilly had previously expressed interest in the French biotech, and the expiration of AstraZeneca's exclusive period would provide a fresh opportunity for them to pursue a takeover.
Founded in 2013 by Philippe Pouletty, Abivax focuses on developing treatments for inflammatory diseases. Its experimental therapy for ulcerative colitis is currently undergoing Phase 3 trials, with commercialization anticipated around 2027. The U.S. market is projected to account for nearly 70% of the drug's potential commercial value, making FDA approval a critical factor.
The acquisition process is further complicated by the impending release of additional Phase 3 maintenance trial data for obefazimod in late June. Prospective bidders might choose to await these results before committing to a final offer. Moreover, French authorities are closely monitoring the situation, with the country's finance ministry indicating that any takeover of a strategic healthcare company would trigger foreign investment scrutiny. AstraZeneca, being a European company, might have a political advantage in this regard compared to a U.S. buyer. AstraZeneca's CEO, Pascal Soriot, who has French and Australian nationality, also shares an established professional relationship with Abivax CEO Marc de Garidel, having previously acquired CinCor Pharma from Garidel in 2023.
As the March 23rd deadline approaches, the pharmaceutical world watches intently to see whether AstraZeneca will secure the deal or if the field will reopen for other eager contenders like Eli Lilly. This potential acquisition highlights the fierce competition among major pharmaceutical companies to enhance their pipelines with innovative therapies and the significant value placed on promising drug candidates in the biotech sector.
The evolving situation surrounding Abivax's potential acquisition underscores the dynamic and competitive nature of the pharmaceutical industry. It highlights the strategic importance of promising drug candidates in pipeline replenishment and the meticulous evaluations involved in such high-value transactions. This scenario also sheds light on the complex interplay between clinical trial results, market valuation, regulatory oversight, and geopolitical considerations that shape the landscape of global pharmaceutical mergers and acquisitions. For investors and healthcare professionals, it serves as a compelling case study on how scientific breakthroughs can rapidly alter a company's trajectory and attract intense interest from industry giants seeking to expand their therapeutic portfolios.